Table 1 Study and participant characteristics
Reference | Country (number of sites) | Participant characteristics | Sample size (intervention group(s)) | Sample size (control group) | Range, mean age (years) | Intervention | GAS utility (primary or secondary outcome) |
|---|---|---|---|---|---|---|---|
Armstrong et al. [29] | Australia (1) | Children with Developmental Delays | 32 | 36 | 1.5–3 years, 2.4 yearsa | Use of LeAP playground in a community centre by children with developmental delays | Secondary |
Cusick et al. [30] | Australia (1) | Children with spastic hemiplegic cerebral palsy | 20 | 21 | 2–7 years, 3.9 years | Botulinum toxin A injections | Primary |
Cusick et al. [31] | Australia (1) | Children with spastic hemiplegic cerebral palsy | 21 | 21 | 2–8 years, 3.9 years | Botulinum toxin A injections | Secondary |
DeJoode et al. [32] | Netherlands (7) | Adults with acquired brain injury | 21 | 13 | 18–75 years, 40.8 years | Use of personal digital assistance as a cognitive aid | Primary |
Dimitrova et al. [33] | Canada, Hungary, Philippines, Poland, Russia, South Korea, Thailand, Turkey, and the United States (40) | Children with upper limb spasticity | 75 for 6 U/kg | 79 | 2–17 years, 7.9 yearsa | Onabotulinumtoxin-A injection plus OT sessions | Secondary |
78 for 3 U/kg | |||||||
Hoare et al. [25] | Australia (1) | Children with congenital spastic unilateral Cerebral Palsy | 17 | 17 | 1.5–6 years, 3 years | Botulinum toxin A injections | Secondary |
Huang et al. [34] | Taiwan (1) | Children with motor delays | ROC-Sit: 15 | 11 | 1–3 years, 1.85 years | Ride-on car training | Secondary |
ROC- Stand: 12 | |||||||
Hwang et al. [25] | Taiwan (8) | Children with or at risk for Developmental Delay | 19 | 16 | 0.42–2.5 years, 1.45 years | Routine based early intervention | Primary |
Leroi et al. [35] | UK (1) | Adults with Parkinson’s disease with dementia | 11 | 13 | Ranges not reported, 75.6 years | Administration of memantine 20 mg daily | Primary |
Lowe et al. [36] | Australia (1) | Children with hemiplegic Cerebral Palsy | 21 | 21 | 2–8 years, 4 years | Botulinum toxin A injections | Secondary |
Lowe et al. [37] | Australia (3) | Children with Cerebral Palsy | 42 | 40 | 2–8 years, 4 years | Botulinum toxin A injections | Secondary |
McKean et al. [38] | Australia (1) | Children with speech disorder | 10 | 10 | 3–6 years, 4.22 years | Family-centred practice | Secondary |
McMorran et al. [26] | UK (1) | Children with Diplegic Cerebral palsy | 30 | 32 | Ranges not reported, 14.5 years | Surgery | Primary |
Mills et al. [39] | Australia (1) | Children with Autism | 16 | 18 | 4–12 years, 7.4 yearsa | School-based sensory activity schedule | Secondary |
Olesch et al. [40] | Australia (1) | Children with hemiplegic cerebral palsy | 11 | 11 | 1.5 to 5 years, 3.67 years | Botulinum toxin A injections | Primary |
Rockwood et al. [18] | Canada (10) | Adults with mild to moderate Alzheimer’s disease | 53 | 56 | 51–94 years, 77.5 years | Galantamine medication | Primary |
Rockwood et al. [27]b | Canada (10) | Adults with mild to moderate Alzheimer’s disease | 53 | 56 | 51–94 years, 77.5 years | Galantamine medication | Primary |
Rockwood et al. [28]b | Canada (10) | Adults with mild to moderate Alzheimer’s disease | 53 | 56 | 51–94 years, 77.5 years | Galantamine medication | Primary |
Schaaf et al. [41] | United States (1) | Children with Autism spectrum disorder | 17 | 14 | 4–8 years, 5.98 yearsa | Manualized intervention for sensory difficulties | Primary |
Schasfoort et al. [42] | Netherlands (7) | Children with spastic cerebral palsy | 41 | 24 | 4–12 years, 7.33 years | BoNT-A injection | Secondary |
Tilton et al. [43] | United States (1) | Children with dynamic foot equinus | 79 for both groups | 76 | 2–17 years, no mean age reported | AbobotulinumtoxinA injection | Primary |